![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Germany's Schering Divests Thrombosis Rights to Pfizer
Germany's Schering Divests Thrombosis Rights to Pfizer
German drug producer Schering AG has sold the development and marketing rights on its ADP-receptor agonist programme to US drug major Pfizer. The study has a portfolio of thrombosis compounds focused on developing oral anti-platelet agents, and under the deal Schering will receive undisclosed up-front fees, milestone payments and royalties from Pfizer. Although the programme is not expected to lead to a new drug approval until 2010, the move is seen as positive for Schering, which is shifting its development activities away from non-core segments such as cardiovascular health.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct